Dong-A signs out-licensing agreement for novel DPP-IV inhibitor with Alkem India

Published: 2012-12-26 06:57:00

Updated: 2012-12-26 06:57:00

Dong-A Pharm announced Friday that it has signed an out-licensing agreement for Dong-A’s novel and selective DPP-IV (dipeptidyl peptidase) inhibitor, DA-1229, with Alkem Laboratories, one of the largest pharmaceutical firms in India.

Under the deal, Dong-A authorized that Alkem would have the exclusive license of research, development, production and marketing for DA-1229, a novel and select...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.